Hyderabad-based Sai Parenterals raises Rs 50 crore from marquee investors

Hyderabad-based Sai Parenterals Limited today announced the completion of Rs 50 crore equity funding round led by a group of marquee investors. The company said the capital will support its growth plans for establishing its international footprint as it pursues its vision to become a global pharmaceutical company.

Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital led the fundraising round.

"We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. This equity infusion will allow us to acquire high-potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities," said Anil Karusala, Managing Director of Sai Parenterals.

"Our second round of investment reflects our strong conviction in Sai Parenterals’ science-driven culture and scalable manufacturing platform. By partnering with a formidable player in sterile injectables, we aim to accelerate affordable, high-quality healthcare solutions for global markets while delivering sustained value to the investors," said Harikrishnan S, Managing Partner of Blue Lotus Capital.

Sai Parenterals is an Indian pharmaceutical company that operates across the pharmaceutical value chain, including research & development (R&D), manufacturing, regulatory compliance, marketing, and exports.

With two strategic business verticals, Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services, Sai Parenterals focuses on delivering value-added drug formulations.

The company has built a diverse portfolio across dosage forms, including injectables, oral solids and liquids, and topical preparations. The company operates five facilities in India, of which some are approved by TGA Australia, GCC, SAPRA and WHO GMP, supporting a growing presence in both domestic and key international markets.